Physician profile
Peter Fast
NPI 1255699435
$1,165.99
in general payments reported to CMS, 2019-2025
15 companies · $76.72 in 2025
The $76.72 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.70 · 2020: $16.00 · 2021: $135 · 2022: $486 · 2023: $305 · 2024: $134 · 2025: $76.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $289.89 | 2022-2023 | Simponi Aria, Simponi, Remicade |
| Sanofi-Aventis U.S. LLC | $194.99 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $168.00 | 2022-2025 | Saphnelo |
| Trice Medical, INC. | $116.91 | 2024 | |
| Amgen INC. | $81.31 | 2021-2023 | Tavneos, Enbrel |
| Ucb, INC. | $56.23 | 2021 | |
| Pacira Therapeutics, INC. | $53.19 | 2019-2021 | |
| Bioventus LLC | $48.20 | 2022-2024 | Durolane, Durolane |
| Stryker Corporation | $37.07 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $22.85 | 2025 | Iovera, Zilretta |
| Horizon Therapeutics Plc | $22.61 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $22.55 | 2025 | Auvelity |
| Pylant Medical | $19.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.13 | 2025 | Spravato |
| Ultragenyx Pharmaceutical INC. | $15.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Fast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.